{"id":30920,"date":"2026-08-09T04:04:00","date_gmt":"2026-08-08T20:04:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=30920"},"modified":"2026-08-09T05:35:58","modified_gmt":"2026-08-08T21:35:58","slug":"nejm%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%81%a9%e8%b5%9b%e7%89%b9%e9%9f%a6%e7%94%a8%e4%ba%8e%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e5%ae%b6%e5%ba%ad%e5%af%86%e6%8e%a5%e7%9a%84%e6%9a%b4","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=30920","title":{"rendered":"[NEJM\u53d1\u8868\u8bba\u6587]\uff1a\u6069\u8d5b\u7279\u97e6\u7528\u4e8e\u65b0\u51a0\u75c5\u6bd2\u5bb6\u5ead\u5bc6\u63a5\u7684\u66b4\u9732\u540e\u9884\u9632"},"content":{"rendered":"\n

ORIGINAL ARTICLE<\/a><\/p>\n\n\n\n

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts<\/h1>\n\n\n\n

Frederick G. Hayden, Masaharu Shinkai, Tristan W. Clark, et al<\/h3>\n\n\n\n

N Engl J Med 2026;394:1905-1915<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

BACKGROUND<\/h3>\n\n\n\n

Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Covid-19.<\/p>\n\n\n\n

METHODS<\/h3>\n\n\n\n

In this double-blind, randomized, placebo-controlled trial, we randomly assigned persons who were SARS-CoV-2\u2013negative on local diagnostic testing but were household contacts of a patient with Covid-19 (the index patient) to receive either ensitrelvir (375 mg on day 1 and 125 mg daily on days 2 through 5) or placebo within 72 hours after symptom onset in the index patient. The primary end point was Covid-19 (defined by a central laboratory\u2013confirmed positive reverse-transcriptase\u2013polymerase-chain-reaction assay and the presence of \u22651 of 14 prespecified Covid-19 symptoms lasting \u226548 hours) by day 10 in a household contact in the modified intention-to-treat population (all the participants who underwent randomization, had a central laboratory\u2013confirmed negative RT-PCR test for SARS-CoV-2 at baseline, and received at least one dose of the trial drug or placebo).<\/p>\n\n\n\n

RESULTS<\/p>\n\n\n\n

The modified intention-to-treat population included 1030 participants in the ensitrelvir group and 1011 in the placebo group. The mean age of the participants was 42.4 years; 71.1% had undergone randomization within 48 hours after symptom onset in the index patient, and 37.0% had at least one risk factor for severe Covid-19. The incidence of Covid-19 was lower in the ensitrelvir group than in the placebo group (2.9% vs. 9.0%; risk ratio, 0.33; 95% confidence interval [CI], 0.22 to 0.49; P<0.001). The incidence of adverse events during the trial was similar in the two groups (15.1% in the ensitrelvir group and 15.5% in the placebo group), as was the incidence of serious adverse events (0.2% in each group). No Covid-19\u2013related hospitalizations or deaths were reported.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n

CONCLUSIONS<\/h3>\n\n\n\n

Ensitrelvir administered to household contacts of a patient with Covid-19 within 72 hours after symptom onset in the index patient was effective in preventing Covid-19 in the contacts. (Funded by Shionogi; SCORPIO-PEP Japan Registry for Clinical Trials number, jRCT2031230124<\/a>; ClinicalTrials.gov number, NCT05897541<\/a>.)<\/p>\n","protected":false},"excerpt":{"rendered":"

ORIGINAL ARTICLE Ensitrelvir for Covid-19 Postexposure […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30920"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30920"}],"version-history":[{"count":4,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30920\/revisions"}],"predecessor-version":[{"id":31399,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30920\/revisions\/31399"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}